High-flow Oxygen for Vaso-occlusive Pain Crisis

NARecruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

April 27, 2020

Primary Completion Date

November 27, 2025

Study Completion Date

November 27, 2025

Conditions
Sickle Cell Disease
Interventions
DEVICE

Stadard low-flow oxygen

In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care

DEVICE

HFNO with low FiO2 (21%-30%)

HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function

DEVICE

HFNO with intermediate FiO2 (50%)

In this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia

DEVICE

HFNO with high FiO2 (100%)

In this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia

Trial Locations (1)

94000

RECRUITING

Henri Mondor, Créteil

All Listed Sponsors
collaborator

Fisher and Paykel Healthcare

INDUSTRY

collaborator

Orkyn'

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER